GlassScriptPhysician profile
Chhavi Manchanda
NPI 1669758983
$7,300.05
in general payments reported to CMS, 2019-2025
49 companies · $1,874 in 2025
The $1,874 reported for 2025 was more than what 77% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $477 · 2021: $867 · 2022: $990 · 2023: $1,302 · 2024: $1,136 · 2025: $1,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,311.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,514.81 | 2019-2025 | Octrode, Eterna, Penta |
| Abbvie INC. | $682.06 | 2021-2025 | |
| Ucb, INC. | $539.18 | 2021-2025 | Nayzilam, Briviact, Zilbrysq |
| Sk Life Science, INC. | $353.92 | 2022-2025 | |
| Medtronic USA, INC. | $326.40 | 2019-2020 | |
| Medtronic, INC. | $320.61 | 2022-2023 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Amneal Pharmaceuticals LLC | $278.03 | 2021-2025 | Crexont, Lyvispah, Rytary |
| Acadia Pharmaceuticals INC | $210.85 | 2019-2025 | Nuplazid |
| Saluda Medical Americas, INC. | $189.42 | 2024-2025 | Evoke |
| Biogen, INC. | $123.09 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Boston Scientific Corporation | $121.37 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Stryker Corporation | $113.54 | 2021-2024 | Multigen 2, Spinejack |
| Allergan, INC. | $95.15 | 2019-2021 | |
| Corium, LLC | $89.14 | 2022-2023 | Adlarity |
| Nevro Corp. | $88.60 | 2019-2022 |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tonix Medicines, INC. | $86.53 | 2025 | Zembrace Symtouch |
| Eisai INC. | $84.68 | 2024 | |
| Neurelis, INC. | $76.83 | 2021-2022 | |
| Kyowa Kirin, INC. | $70.64 | 2019-2021 | |
| Merz North America, INC. | $66.30 | 2019-2020 | |
| Bioventus LLC | $58.16 | 2023-2025 | Durolane, Durolane |
| Novartis Pharmaceuticals Corporation | $50.43 | 2022-2023 | |
| Avanos Medical | $48.82 | 2024 | Generator |
| Banner Life Sciences, LLC | $46.04 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $45.74 | 2024-2025 | Ingrezza |
| Grt US Holding, INC. | $44.67 | 2020-2021 | |
| Alnylam Pharmaceuticals INC. | $44.58 | 2023 | Givlaari |
| Upsher-Smith Laboratories LLC | $41.43 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $39.97 | 2024-2025 | Austedo Xr, Austedo Xr |
| Emd Serono, INC. | $38.74 | 2020 | |
| Pfizer INC. | $37.74 | 2019-2025 | |
| Grifols USA, LLC | $31.06 | 2025 | Gamunex-C |
| Tanabe Pharma America, INC. | $30.37 | 2019-2022 | |
| Argenx US, INC. | $28.43 | 2023 | Vyvgart Hytrulo |
| Lilly USA, LLC | $28.41 | 2023-2025 | Kisunla, Reyvow, Emgality |
| Genentech USA, INC. | $28.13 | 2025 | Ocrevus Zunovo |
| Catalyst Pharmaceuticals, INC. | $25.24 | 2025 | |
| Vertiflex, INC. | $23.50 | 2019 | |
| Painteq LLC | $22.21 | 2024 | Painteq |
| Impel Pharmaceuticals LLC | $20.01 | 2025 | Trudhesa |
| Impel Pharmaceuticals INC. | $19.63 | 2022 | |
| Avion Pharmaceuticals | $19.39 | 2022 | |
| C2n Diagnostics, LLC | $18.47 | 2025 | Precivityad2 |
| Lundbeck LLC | $15.55 | 2025 | Rexulti |
| Ge Healthcare | $15.26 | 2024 | |
| Amgen INC. | $15.25 | 2022 | |
| Livanova USA, INC. | $12.88 | 2020 | |
| Zyla Life Sciences, INC. | $11.70 | 2020 | |
| Electronic Waveform Lab, INC. | $7.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chhavi Manchanda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.